Skip to main content
Download PDF

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Arthritis Research & Therapy volume 22, Article number: 155 (2020) Cite this article

The Original Article was published on 12 March 2020

Correction to: Arthritis Research & Therapy (2020) 22:47

https://doi.org/10.1186/s13075-020-2125-2

Following publication of the original article [1], the authors identified an error in the 95% CI bars plotted on the graphs of Fig. 6a, b, and c. The CI numbers in the table below the graph are correct, but the upper and lower limit bars plotted on the graph are incorrect. The corrected Fig. 6 is given below.

Fig. 6
figure 1

Adverse events of special interest per 100 patient-years during the overall period: a serious infections, b herpes zoster-related disease, c malignancies (SAF). Patient-years was calculated from initial dose up to first incidence of the event for patients who had at least one event, and from initial dose through follow up for patients who had no events; IR was calculated as (100 × number of patients with ≥ 1 incidence/total patient-years) CI confidence interval, IR incidence rate

Full size image

Reference

  1. Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther. 2020;22:47. https://doi.org/10.1186/s13075-020-2125-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Tsutomu Takeuchi and Yoshiya Tanaka contributed equally to this work.

Authors and Affiliations

  1. Keio University School of Medicine, Tokyo, Japan

    Tsutomu Takeuchi

  2. University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Yoshiya Tanaka

  3. University of Tokyo, Tokyo, Japan

    Sakae Tanaka

  4. Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Atsushi Kawakami

  5. Seoul National University, Seoul National University Hospital, Seoul, South Korea

    Yeong-Wook Song

  6. Taichung Veterans General Hospital, Taichung, Taiwan

    Yi-Hsing Chen

  7. Astellas Pharma, Inc., Tokyo, Japan

    Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi & Emi Yamada

Authors
  1. Tsutomu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sakae Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsushi Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yeong-Wook Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-Hsing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitsuhiro Rokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Izutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoshi Ushijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuichiro Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshihiro Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Teruaki Shiomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Takeuchi.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeuchi, T., Tanaka, Y., Tanaka, S. et al. Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther 22, 155 (2020). https://doi.org/10.1186/s13075-020-02247-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13075-020-02247-3

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us